| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Peter F Buckley, Nina R Schooler, Donald C Goff, John Hsiao, Alexander Kopelowicz, John Lauriello, Theo Manschreck, Alan J Mendelowitz, Del D Miller, Joanne B Severe, Daniel R Wilson, Donna Ames, Juan Bustillo, Jim Mintz, John M Kan. Comparison of SGA oral medications and a long-acting injectable SGA: the PROACTIVE study. Schizophrenia bulletin. vol 41. issue 2. 2016-01-25. PMID:24870446. |
at 8 us academic centers, 305 patients with schizophrenia or schizoaffective disorder were randomly assigned to lai risperidone (lai-r) or physician's choice oral sgas. |
2016-01-25 |
2023-08-13 |
Not clear |
| Hiroyoshi Takeuchi, Gary Remingto. Improving symptoms and side effects in older patients with schizophrenia with decreasing dopamine D2/3 receptor occupancy following risperidone and olanzapine dose reduction. Evidence-based mental health. vol 18. issue 4. 2016-01-22. PMID:26459470. |
improving symptoms and side effects in older patients with schizophrenia with decreasing dopamine d2/3 receptor occupancy following risperidone and olanzapine dose reduction. |
2016-01-22 |
2023-08-13 |
Not clear |
| Satoko Baba, Takeshi Murai, Tomokazu Nakako, Takeshi Enomoto, Michiko Ono, Isao Shimizu, Kazuhito Iked. The serotonin 5-HT₁A receptor agonist tandospirone improves executive function in common marmosets. Behavioural brain research. vol 287. 2016-01-19. PMID:25804359. |
these results suggest that tandospirone is a promising candidate for the treatment of cognitive deficits associated with schizophrenia and that adjunctive treatment with tandospirone and blonanserin is more appropriate for cognitive deficits than combination therapy with tandospirone and risperidone or haloperidol. |
2016-01-19 |
2023-08-13 |
Not clear |
| Atul Sherje, Vaishali Londh. Inclusion Complexes of Hydroxy Propyl-β-Cyclodextrin and Paliperidone: Preparation and Characterization. Current drug discovery technologies. vol 11. issue 4. 2015-12-29. PMID:25578059. |
it is a major active metabolite of risperidone approved for the treatment of schizophrenia in adults. |
2015-12-29 |
2023-08-13 |
Not clear |
| Mohammad-Reza Khodaie-Ardakani, Mohsen Khosravi, Razieh Zarinfard, Somayeh Nejati, Ali Mohsenian, Mina Tabrizi, Shahin Akhondzade. A Placebo-Controlled Study of Raloxifene Added to Risperidone in Men with Chronic Schizophrenia. Acta medica Iranica. vol 53. issue 6. 2015-12-29. PMID:26069170. |
a placebo-controlled study of raloxifene added to risperidone in men with chronic schizophrenia. |
2015-12-29 |
2023-08-13 |
Not clear |
| Mohammad-Reza Khodaie-Ardakani, Mohsen Khosravi, Razieh Zarinfard, Somayeh Nejati, Ali Mohsenian, Mina Tabrizi, Shahin Akhondzade. A Placebo-Controlled Study of Raloxifene Added to Risperidone in Men with Chronic Schizophrenia. Acta medica Iranica. vol 53. issue 6. 2015-12-29. PMID:26069170. |
in a randomized, double-blind and placebo-controlled study, forty-six male patients diagnosed with schizophrenia (dsm-iv-tr), were randomized to either raloxifene (120 mg/day) or placebo in addition to risperidone (6 mg/day) for eight weeks. |
2015-12-29 |
2023-08-13 |
Not clear |
| Hiroyoshi Takeuchi, Gagan Fervaha, Jimmy Lee, Ofer Agid, Gary Remingto. Effectiveness of different dosing regimens of risperidone and olanzapine in schizophrenia. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. vol 25. issue 3. 2015-12-15. PMID:25649680. |
effectiveness of different dosing regimens of risperidone and olanzapine in schizophrenia. |
2015-12-15 |
2023-08-13 |
Not clear |
| Hiroyoshi Takeuchi, Gagan Fervaha, Jimmy Lee, Ofer Agid, Gary Remingto. Effectiveness of different dosing regimens of risperidone and olanzapine in schizophrenia. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. vol 25. issue 3. 2015-12-15. PMID:25649680. |
the objective of this study was to evaluate the effectiveness and impact of once- versus twice-daily dosing of risperidone and olanzapine on clinical outcomes in patients with schizophrenia. |
2015-12-15 |
2023-08-13 |
Not clear |
| Hiroyoshi Takeuchi, Gagan Fervaha, Jimmy Lee, Ofer Agid, Gary Remingto. Effectiveness of different dosing regimens of risperidone and olanzapine in schizophrenia. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. vol 25. issue 3. 2015-12-15. PMID:25649680. |
patients with schizophrenia were randomly allocated to treatment with risperidone and olanzapine, and were also randomly assigned to once-daily (n=173 and 169, respectively) or twice-daily (n=168 and 167, respectively) dosing and followed for up to 18 months. |
2015-12-15 |
2023-08-13 |
Not clear |
| Mehran Mortazavi, Davood Farzin, Mehran Zarhghami, Seyed Hamzeh Hosseini, Parisa Mansoori, Gholamreza Nategh. Efficacy of Zinc Sulfate as an Add-on Therapy to Risperidone Versus Risperidone Alone in Patients With Schizophrenia: A Double-Blind Randomized Placebo-Controlled Trial. Iranian journal of psychiatry and behavioral sciences. vol 9. issue 3. 2015-11-20. PMID:26576178. |
efficacy of zinc sulfate as an add-on therapy to risperidone versus risperidone alone in patients with schizophrenia: a double-blind randomized placebo-controlled trial. |
2015-11-20 |
2023-08-13 |
Not clear |
| J Zhang, L Ye, W Wang, G Du, X Yu, X Zhu, Q Dong, X Cen, X Guan, F Fu, J Tia. A 12-week subchronic intramuscular toxicity study of risperidone-loaded microspheres in rats. Human & experimental toxicology. vol 34. issue 2. 2015-11-16. PMID:24812153. |
risperidone, a serotoninergic 5-ht2 and dopaminergic d2 receptor antagonist, was developed to be a long-acting sustained-release formulation for the treatment of schizophrenia. |
2015-11-16 |
2023-08-13 |
rat |
| Cinzia Niolu, Emanuela Bianciardi, Giorgio Di Lorenzo, Claudia Marchetta, Ylenia Barone, Nicoletta Sterbini, Michele Ribolsi, Giorgio Reggiardo, Alberto Siracusan. Enhancing adherence, subjective well-being and quality of life in patients with schizophrenia: which role for long-acting risperidone? Therapeutic advances in psychopharmacology. vol 5. issue 5. 2015-11-11. PMID:26557984. |
enhancing adherence, subjective well-being and quality of life in patients with schizophrenia: which role for long-acting risperidone? |
2015-11-11 |
2023-08-13 |
human |
| Mei Han, Xiang Yang Zhang, Da Chun Chen, Yun Long Tan, Chong Sheng Song, Ying Hua Yu, Xu Feng Huan. Cognitive differences in schizophrenia on long-term treatments with clozapine, risperidone and typical antipsychotics. International clinical psychopharmacology. vol 30. issue 2. 2015-11-06. PMID:25568968. |
cognitive differences in schizophrenia on long-term treatments with clozapine, risperidone and typical antipsychotics. |
2015-11-06 |
2023-08-13 |
Not clear |
| Mei Han, Xiang Yang Zhang, Da Chun Chen, Yun Long Tan, Chong Sheng Song, Ying Hua Yu, Xu Feng Huan. Cognitive differences in schizophrenia on long-term treatments with clozapine, risperidone and typical antipsychotics. International clinical psychopharmacology. vol 30. issue 2. 2015-11-06. PMID:25568968. |
cognitive function was assessed in 418 patients with schizophrenia on long-term treatment with apds (215 on clozapine, 91 on risperidone and 112 on typical apds) and 159 healthy controls using the repeatable battery for the assessment of neuropsychological status (rbans). |
2015-11-06 |
2023-08-13 |
Not clear |
| Kenneth L Subotnik, Laurie R Casaus, Joseph Ventura, John S Luo, Gerhard S Hellemann, Denise Gretchen-Doorly, Stephen Marder, Keith H Nuechterlei. Long-Acting Injectable Risperidone for Relapse Prevention and Control of Breakthrough Symptoms After a Recent First Episode of Schizophrenia. A Randomized Clinical Trial. JAMA psychiatry. vol 72. issue 8. 2015-10-30. PMID:26107752. |
long-acting injectable risperidone for relapse prevention and control of breakthrough symptoms after a recent first episode of schizophrenia. |
2015-10-30 |
2023-08-13 |
Not clear |
| Sung-Wan Kim, Bo-Ok Jeong, Jae-Min Kim, Il-Seon Shin, Michael Y Hwang, G Paul Amminger, Barnaby Nelson, Michael Berk, Patrick McGorry, Jin-Sang Yoo. Associations of obsessive-compulsive symptoms with clinical and neurocognitive features in schizophrenia according to stage of illness. Psychiatry research. vol 226. issue 1. 2015-10-21. PMID:25681006. |
this study enrolled 163 people with schizophrenia who were receiving risperidone monotherapy. |
2015-10-21 |
2023-08-13 |
human |
| Leslie Citrome, Peter J Weiden, Gus Alva, Ira D Glick, Richard Jackson, Greg Mattingly, Farid Kianifard, Xiangyi Meng, Adam Winsec. Switching to iloperidone: An omnibus of clinically relevant observations from a 12-week, open-label, randomized clinical trial in 500 persons with schizophrenia. Clinical schizophrenia & related psychoses. vol 8. issue 4. 2015-10-19. PMID:25367165. |
to describe secondary analyses from a 12-week, randomized, open-label trial where adult schizophrenia outpatients receiving risperidone, olanzapine, or aripiprazole were switched to iloperidone. |
2015-10-19 |
2023-08-13 |
Not clear |
| Tatiana Dilla, Jörgen Möller, Paul O'Donohoe, María Álvarez, José A Sacristán, Michael Happich, Antje Tockhor. Long-acting olanzapine versus long-acting risperidone for schizophrenia in Spain - a cost-effectiveness comparison. BMC psychiatry. vol 14. 2015-10-16. PMID:25438678. |
long-acting olanzapine versus long-acting risperidone for schizophrenia in spain - a cost-effectiveness comparison. |
2015-10-16 |
2023-08-13 |
Not clear |
| Tatiana Dilla, Jörgen Möller, Paul O'Donohoe, María Álvarez, José A Sacristán, Michael Happich, Antje Tockhor. Long-acting olanzapine versus long-acting risperidone for schizophrenia in Spain - a cost-effectiveness comparison. BMC psychiatry. vol 14. 2015-10-16. PMID:25438678. |
the aim of this study was to assess the cost-effectiveness of olanzapine long-acting injection (olai) compared with risperidone long-acting injection (rlai) in patients with schizophrenia in spain. |
2015-10-16 |
2023-08-13 |
Not clear |
| Marilena Gilca, Gabriela Piriu, Laura Gaman, Corina Delia, Liviu Iosif, Valeriu Atanasiu, Irina Stoia. A study of antioxidant activity in patients with schizophrenia taking atypical antipsychotics. Psychopharmacology. vol 231. issue 24. 2015-10-13. PMID:24871701. |
the aims of this study were to investigate the antioxidative activity of paraoxonase and assess lipid profile as a cardiovascular risk factor in patients with schizophrenia under long-term clozapine or risperidone treatment. |
2015-10-13 |
2023-08-13 |
Not clear |